一种Spike-Accum生物结合蛋白疫苗赋予了强大的SARS-CoV-2特异性免疫力
Jean Pierre Bikorimana1, Nathanael A Caveney2,3, Nehme El-Hachem4
1Department of Microbiology, Infectious Diseases, and Immunology, Université de Montréal, Montreal, QC H3T 1J4, Canada.
iScience
|October 7, 2025
概括
使用Accum技术的新型Spike蛋白疫苗增强了对SARS-CoV-2变种的抗体反应. 这种安全有效的疫苗加速了子的病毒清除,为未来的流行病准备提供了有希望的工具.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 蛋白质工程是指蛋白质工程.
- 免疫学 免疫学 免疫学
背景情况:
- 随着COVID-19的爆发,人们迫切需要快速开发针对新出现的传染病的疫苗.
- 有效的疫苗对于减轻未来病毒爆发和流行病的影响至关重要.
研究的目的:
- 开发和评估一种基于Spike (Sp) 蛋白质的新型疫苗,利用Accum平台提高免疫性和疗效.
- 评估Sp-Accum疫苗对SARS-CoV-2感染的安全性和保护潜力.
主要方法:
- 斯派克蛋白与Accum平台的生物结合.
- 对抗体标位,特异性,Sp-ACE2相互作用的中和性和与SARS-CoV-2变种的交叉反应性的评估.
- 在子中的免疫性评估和在SARS-CoV-2仓鼠模型中的疗效/安全研究.
主要成果:
- Sp-Accum生物结合维持了蛋白质结构,同时诱导了特定于S1域的高抗体标位.
- 该疫苗有效中和了Sp-ACE2相互作用,并证明了与多种Sp变体的交叉反应性.
- 在仓鼠中,疫苗是安全的,加速病毒清除,并预防肺炎.
结论:
- Accum平台使增值蛋白质疫苗的开发成为可能,这些疫苗具有增强的免疫性质.
- 这项概念验证研究突出了Accum技术的多功能性,用于快速设计针对未来流行病威胁的疫苗.
更多相关视频
06:39High-throughput Confocal Imaging of Quantum Dot-Conjugated SARS-CoV-2 Spike Trimers to Track Binding and Endocytosis in HEK293T Cells
Published on: April 21, 2022
3.5K
08:07Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
Published on: January 12, 2024
1.2K
相关概念视频
Conjugated Proteins
27.5K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
27.5K
Vaccinations
51.2K
Overview
51.2K
Enzyme-Linked Immunosorbent Assay
17.3K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...
17.3K
Immune Response Against Viral Pathogens
1.7K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.7K
Humoral Immune Responses
83.3K
Overview
83.3K
